SLAMF7 靶点蛋白|抗体药物|临床药物信息

SLAMF7信息

英文名称：SLAM family member 7
中文名称：SLAM家族成员-7
靶点别称：Novel Ly9，CS1，CD_antigen=CD319，Membrane protein FOAP-12，CRACC，SLAMF7，Protein 19A，SLAM family member 7，CD2 subset 1，CD2-like receptor-activating cytotoxic cells

上市药物数量：1
临床药物数量：4
最高研发阶段：批准上市

SLAMF7产品列表

筛选结果

产品库

在线 (7)

物种

标签

属性

Protein (7)

标记

货号	物种	产品描述
SL7-H5225	Human	Human SLAMF7 / CRACC / CD319 Protein, His Tag
SL7-H5256	Human	Human SLAMF7 /CD319 /CRACC Protein, C-Fc Tag
SL7-H82E0	Human	Biotinylated Human SLAMF7 / CRACC / CD319 Protein, Avitag,His Tag
SL7-M5252	Mouse	Mouse SLAMF7 / CRACC / CD319 Protein, Mouse IgG2a Fc Tag, low endotoxin
SL7-R52H7	Rhesus macaque	Rhesus macaque SLAMF7 / CRACC / CD319 Protein, His Tag
SL7-HF2H7	Human	FITC-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag
SL7-HP2H3	Human	PE-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag

SLAMF7 Molecule Synonym Name

SLAMF7,CD319,CS1,CRACC,19A,FOAP-12

SLAMF7 分子背景

SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.

SLAMF7 参考文献

SLAMF7上市药物信息

英文名称	中文名称	研发代码	研发阶段	公司	最早商品名	最早批准国家	最早适应症	最早批准公司	最早批准日期	适应症	临床试验
Elotuzumab		HuLuc-63; BMS-901608; PDL-063	批准上市	艾伯维, 百时美施贵宝	EMPLICITI	fda	多发性骨髓瘤	BRISTOL MYERS SQUIBB	2015-11-30	多发性骨髓瘤	详情

SLAMF7临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
UCART-CS1	UCART-CS1; UCART-38	临床一期	Cellectis, M.D. Anderson Cancer Center	多发性骨髓瘤	详情
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics)		临床一期	iCell Gene Therapeutics	多发性骨髓瘤	详情
Azintuxizumab vedotin	ABBV-838	临床一期	艾伯维	多发性骨髓瘤	详情
CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology)		临床阶段不明	武汉波睿达生物科技有限公司, 同济医院	血液系统恶性肿瘤

会议日历

会议一览

SLAMF7 重组蛋白